$10.3 Billion Merger

Kite Pharma is selling itself too cheaply through an unfair process to Gilead Sciences, for $180 a share or $10.3 billion, shareholders say in a federal <a href="http://www.courthousenews.com/wp-content/uploads/2017/09/Kite.Gilead.pdf"><strong>class action</strong></a>.

LOS ANGELES — Kite Pharma is selling itself too cheaply through an unfair process to Gilead Sciences, for $180 a share or $10.3 billion, shareholders say in a federal class action.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.